No Data
Shareholder ALI HEALTH has cumulatively reduced its shareholding by 10.0489 million shares.
Hua Ren Health (301408.SZ) announced that the company's Shareholder ALI HEALTH Technology (China) Co., Ltd. (referred to as "Ali...")
Chinese Health (301408.SZ): ALI HEALTH has reduced its shareholding by a cumulative 1.2%.
On February 14, Gelonghui reported that ALI HEALTH (301408.SZ) announced that the company recently received a notification from shareholder ALI HEALTH regarding a Shareholding reduction that reached 1%. It is understood that ALI HEALTH has cumulatively reduced its shareholding in the company by 4,808,277 shares through centralized bidding and block trading, accounting for 1.20% of the company's total share capital. After this equity change, ALI HEALTH holds 25,241,096 shares in the company, accounting for 6.31% of the total share capital.
Anhui Huaren Health Pharmaceutical Co., Ltd.'s (SZSE:301408) Stock Is Going Strong: Have Financials A Role To Play?
Chinese Health (301408.SZ): The wholly-owned subsidiary has obtained the Pharmaceutical registration certificate for glucosamine sulfate capsules.
On February 11th, Gelonghui reported that China Health (301408.SZ) announced that its wholly-owned subsidiary, Anhui Chinese Health Pharmaceutical Co., Ltd., recently received a "Pharmaceutical Registration Certificate" (Certificate No: 2025S00415) issued by the National Medical Products Administration for glucosamine sulfate capsules (hereinafter referred to as "the Pharmaceutical"). The main ingredients of the Pharmaceutical are glucosamine sulfate and sodium chloride. Glucosamine is a natural amino monosaccharide and a precursor material for the synthesis of polysaccharides, which can stimulate chondrocytes to produce proteoglycans with normal polymer structures, thereby enhancing chondrocytes.
China Health (301408.SZ): The application for the registration and marketing authorization of Sacubitril/Valsartan Sodium Tablets has been accepted.
Hua Ren Health (301408.SZ) announced that its wholly-owned subsidiary Jiangsu Shenhua Pharmaceutical Co., Ltd. has received the national pharmaceutical...
Insiders Were the Biggest Winners as Anhui Huaren Health Pharmaceutical Co., Ltd.'s (SZSE:301408) Market Cap Grew by CN¥508m Last Week
Could The Market Be Wrong About Anhui Huaren Health Pharmaceutical Co., Ltd. (SZSE:301408) Given Its Attractive Financial Prospects?
